3 new cardiology updates changing patient care

By MDLinx staffPublished October 8, 2025

Industry Buzz

This updated guideline is designed to support health care professionals—from primary care teams to specialists, and to all clinicians across health systems—with the diagnosis and care of people with high blood pressure.

— Daniel W. Jones, MD, FAHA

In the past few months, cardiovascular prevention has undergone a quiet but significant recalibration.

Three new developments—the finding that 99% of people have at least one modifiable risk factor before a major cardiac event, the release of new high blood pressure guidelines emphasizing earlier and more personalized intervention, and the growing consensus to scale back aspirin use for primary prevention—together signal a shift in how clinicians should think about risk, timing, and prevention.

The common theme? Cardiovascular risk is nearly universal, but not uniformly managed. From fine-tuning when to treat “borderline” hypertension, to reevaluating which patients actually benefit from aspirin, these updates push physicians to act earlier where it helps—and to hold back where it doesn’t.

Nearly universal modifiable risk before cardiac events

A recent, large-scale study reinforces a sobering principle: More than 99% of individuals who go on to have a heart attack, stroke, or heart failure show at least one modifiable risk factor in the lead-up. ^[]

The investigators looked at both South Korean and US cohorts, assessing not just formal diagnoses (e.g. of hypertension or diabetes) but subtler, non-optimal levels of blood pressure, cholesterol, and glucose—even in patients not labeled “hypertensive” or “pre-diabetic.” The takeaway: almost no one “slips through the cracks” completely healthy.

From a clinical standpoint, this is a clarion call: Even mild elevations or borderline metrics shouldn’t be dismissed. The concept of a “silent” or “idiopathic” cardiovascular event, at least in terms of lacking any modifiable risk factor, becomes increasingly hard to defend.

In essence: prevention matters—and early, even modest, intervention may shift that 99% downward.

The 2025 hypertension guideline: Prevention, early treatment, broader lens

In August 2025, the AHA/ACC (with multiple endorsing societies) published a new guideline for the prevention, detection, evaluation, and management of high blood pressure in adults—the first major update since 2017. ^[]

Key shifts:

Use of the PREVENT risk tool: The guideline now recommends using the PREVENT (Predicting Risk of cardiovascular disease Events) calculator to estimate 10- and 30-year cardiovascular risk, incorporating not just BP and cholesterol but kidney function, metabolic measures, and even zip code as a proxy for social determinants. The goal: to better personalize when—and how aggressively—to act.
Emphasis on earlier pharmacotherapy when indicated: The authors argue for treating elevated BP (and stage 1 hypertension) earlier where risk is nontrivial, partly out of concern not just for vascular outcomes but for brain health, cognitive decline, and dementia.
Expanded laboratory screening and etiologic evaluation: Whereas earlier iterations relegated some tests to “optional,” the 2025 guideline more strongly endorses routine checking of urine albumin-to-creatinine ratio (for kidney damage) and broader consideration of aldosterone-to-renin ratios to unmask primary aldosteronism, especially in higher-risk or stage 2 hypertension.
Pregnancy, postpartum, and life course considerations: The guideline gives more attention to BP in pregnancy (and postpartum follow-up), advocating more vigilance and tighter control in some settings.
Unchanged BP thresholds, but shifted philosophy: The numeric thresholds remain as in 2017 (normal < 120/80, elevated 120–129/<80, stage 1 130–139/80–89, stage 2 ≥ 140/90), but the mindset shifts: Act sooner, tailor more, prevent more aggressively.

Clinically, you may now find yourself confronting patients with “borderline” pressure who merit not just lifestyle advice but closer surveillance or even pharmacotherapy, especially if their PREVENT score is concerning.

“This updated guideline is designed to support health care professionals—from primary care teams to specialists, and to all clinicians across health systems—with the diagnosis and care of people with high blood pressure," said chair of the guideline writing committee Daniel W. Jones, MD, FAHA. ^[]

Rethinking aspirin in primary prevention

The third shift challenges a long-held reflex: Routine low-dose aspirin for primary prevention in middle-aged adults. ^[]

A recent reassessment (e.g. using the PREVENT equations in JAMA Internal Medicine) suggests that many middle-aged adults currently using aspirin may derive little net benefit—and indeed may be exposed to unnecessary bleeding risk.

Meanwhile, US Preventive Services Task Force guidance (2022) already recommended against initiating low-dose aspirin in those ≥ 60 years, and urged individualized decision-making in ages 40–59 with ≥ 10 % 10-year CVD risk.

In short: Aspirin is no longer a “set it and forget it” default. Its role is narrowing, and clinicians will increasingly need to weigh ischemic vs bleeding risk in a more nuanced, individualized way.

Pulling it together: What should clinicians watch, adjust, and debate?

Recalibrate your threshold for “action.” With the new hypertension emphasis and the 99% risk-factor finding, patients who used to be “just borderline” now warrant closer monitoring, perhaps earlier initiation of therapy—even when one single metric isn’t wildly off.
Embed risk stratification tools (like PREVENT) into workflow. These aren’t optional extras—they become the lens through which decisions on therapy intensity should go.
Refine aspirin decision-making. Stop thinking in terms of “should all 50-year-olds be on aspirin?” Instead, consider: Does this 50-something patient, with these risk factors and bleeding risk, derive net benefit? The answer may be no in many cases.
Leverage lab and etiologic evaluation. The new BP guideline’s push to expand testing (e.g. albuminuria, renin/aldosterone) should provoke earlier recognition of secondary or contributory causes, allowing more precise therapy.
Tie cardiovascular prevention more tightly to brain health. The growing emphasis on cognition and dementia risk, especially in the hypertension guideline, reminds us that vascular risk management is not just about arteries and ischemia but about preserving neural function long term.
Communicate risk more compellingly to patients. The idea that “99% had modifiable risk before event” is a powerful narrative. Patients may respond better to the framing: “Almost no one who has a heart attack was risk-factor free beforehand.”

SHARE THIS ARTICLE